Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_4

20%

Ph phase_3

40%

Ph not_applicable

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 3Large-scale testing

2(50.0%)

Phase 4Post-market surveillance

1(25.0%)

N/ANon-phased studies

1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(1)

Detailed Status

Completed4

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 32 (50.0%)

Phase 41 (25.0%)

N/A1 (25.0%)

Trials by Status

withdrawn120%

completed480%

Recent Activity

0 active trials

Showing 5 of 5

completed

Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom

NCT01206361

completedphase_4

A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

NCT01168414

Clinical Trials (5)

Showing 5 of 5 trials

NCT01206361

Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom

Completed

NCT00828906Phase 4

DuoTrav® Eye Drops As Replacement Therapy Program

Completed

NCT01542710Not Applicable

Bimatoprost/Timolol Versus Travoprost/Timolol

Completed

NCT00862472Phase 3

Safety and Efficacy Study of DuoTrav APS Versus DuoTrav

Withdrawn

NCT01168414Phase 3

A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5